From the original announcement of acceptance of submission:
Acrux has submitted an ANDA application to the FDA for Lidocaine 2.5% and Prilocaine
2.5% cream, which has now been accepted for review
• Annual sales for the product were US$35m as measured by IQVIA 1
• The product is used as a topical anaesthetic
• The announcement marks Acrux’s third product accepted for review by the FDA
So... kinda? Bit of both?
From the original announcement of acceptance of submission:Acrux...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.44M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 116666 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.4¢ | 50000 | 1 |
View Market Depth
| Last trade - 07.00am 11/07/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable